Welcome @AmoebaNature as a featured exhibitor at the BioSolutions Conference & Expo!

Amoéba is an innovative #greentech company providing the industry with disruptive & sustainable solutions for key resource treatment. Learn more at


📣 Communiqué de presse :
#Amoéba annonce l’annulation de l’émission de la 8° tranche optionnelle d’OCA et la signature d’un contrat avec Redbridge Debt and Treasury Advisory afin d’adapter sa stratégie financière aux enjeux de transformation industrielle

📣 Communiqué de presse :
#Amoéba confirme son éligibilité au dispositif PEA-PME. Les #actions AMOEBA peuvent donc être intégrées dans les portefeuilles PEA PME, dédiés aux #investissements dans les #PME et #ETI selon les critères réglementaires.

🎥 @Fabrice Plasson, PDG d’#Amoéba, revient sur cette année exceptionnelle dans une vidéo dédiée au #bilan 2022 et aux #perspectives 2023. AMM, nouvelle usine, stratégie, plan de financement, tant de sujets abordés sur la chaîne #YouTube d’#Amoéba :

US EPA approves Amoeba’s biocide in the US

US EPA approves Amoeba’s biocide for use in closed cooling systems

Lyon (France), Décember 20th, 2022 – 17h45 – AMOÉBA (FR0011051598 – ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in development phase, informs that the US Environmental Protection Agency (US EPA) has approved the use of the Willaertia magna C2c Maky as an active substance for use cooling systems.

As a result of the EPA’s favorable pre-decision (see Press Release dated August 10th, 2022) and the public consultation required for any new active substance, completed on December 3rd, 2022, the amoeba Willaertia magna C2c Maky and the BIOMEBA products containing it are now approved in the United States for a biocidal use in closed cooling systems for the control of microbial slime (bioslime), microbially induced corrosion and general microbial flora.

After more than 10 years of research and development, Amoéba is the very first company in the world to validate a biological biocide in the treatment of bacterial risk in water! This is a major success that the company will tend to develop over the next few years”, says Fabrice Plasson, CEO of Amoéba.

Besides, to continue the strategic alignment of the company, Amoéba has initiated the withdrawal of the biocidal active substance application in Europe, as was done in Canada (see Press Release dated October 19th, 2022).